Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Staber PB, et al. Among authors: herling m. Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Blood. 2019. PMID: 31292114 Free PMC article. Review.
T-cell prolymphocytic leukemia involving extramedullary sites.
Valbuena JR, Herling M, Admirand JH, Padula A, Jones D, Medeiros LJ. Valbuena JR, et al. Among authors: herling m. Am J Clin Pathol. 2005 Mar;123(3):456-64. doi: 10.1309/93P4-2RNG-5XBG-3KBE. Am J Clin Pathol. 2005. PMID: 15716243
T-cell prolymphocytic leukemia: a single-institution experience.
Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. Ravandi F, et al. Among authors: herling m. Clin Lymphoma Myeloma. 2005 Nov;6(3):234-9. doi: 10.3816/CLM.2005.n.051. Clin Lymphoma Myeloma. 2005. PMID: 16354329
Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.
Reinart N, Nguyen PH, Boucas J, Rosen N, Kvasnicka HM, Heukamp L, Rudolph C, Ristovska V, Velmans T, Mueller C, Reiners KS, von Strandmann EP, Krause G, Montesinos-Rongen M, Schlegelberger B, Herling M, Hallek M, Fingerle-Rowson G. Reinart N, et al. Among authors: herling m. Blood. 2013 Jan 31;121(5):812-21. doi: 10.1182/blood-2012-05-431452. Epub 2012 Nov 1. Blood. 2013. PMID: 23118218 Free article.
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.
Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M, Krönke M, Hallek M, Pogge von Strandmann E. Reiners KS, et al. Among authors: herling m. Blood. 2013 May 2;121(18):3658-65. doi: 10.1182/blood-2013-01-476606. Epub 2013 Mar 18. Blood. 2013. PMID: 23509156 Free PMC article.
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M. Hopfinger G, et al. Among authors: herling m. Cancer. 2013 Jun 15;119(12):2258-67. doi: 10.1002/cncr.27972. Epub 2013 Mar 19. Cancer. 2013. PMID: 23512246 Free article. Clinical Trial.
163 results